INNATE PHARMA (EPA:IPH) Half-year report on INNATE PHARMA's liquidity contract with NATIXIS SECURITIES

Transparency directive : regulatory news

07/01/2011 17:45

Press release

HALF-YEAR REPORT ON INNATE PHARMA'S LIQUIDITY CONTRACT WITH NATIXIS SECURITIES

Marseilles, France, January 7, 2011

Under the liquidity contract entrusted by Innate Pharma to Natixis Securities,
the following assets appeared on the liquidity account as at December 31, 2010:

    133,129 shares of Innate Pharma, and
    10,378.28 euros in cash.

For information, the following assets appeared on the liquidity account at the
latest report:

    108,104 shares of Innate Pharma, and
    51,728.95 euros in cash.

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. It has two proprietary clinical-stage drug candidates: IPH 1101, a small
molecule agonist of gamma delta T cells, has achieved proof-of-concept in two
Phase IIa trials, in type C viral hepatitis and follicular lymphoma. IPH 2101,
an anti-KIR monoclonal antibody potentiating NK cells activation, is currently
in Phase II clinical trials in hematologic cancers. Innate Pharma is also
developing a preclinical portfolio of immunomodulatory or cytotoxic monoclonal
antibodies. Two of its preclinical programs in chronic inflammation have been
out-licensed to Novo Nordisk A/S.

Innate Pharma's key expertise is in immunopharmacology and antibody technology.
The Company has implemented in-house a large panel of molecular and cellular
assays and in vivo models for assessing the pharmacodynamics and
pharmacotoxicology of drug candidates. In addition, Innate Pharma has access to
a very large set of unique research tools in cellular immunology through its
worldwide network of scientific collaborations.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma
is based in Marseilles, France, and had 84 employees as at September 30, 2010.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code             FR0010331421
Ticker code           IPH

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Document de Reference prospectus
filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                  Alize Public Relations
Laure-Hélène Mercier           Caroline Carmagnol
Director, Investor Relations   Phone: +33 (0)1 41 22 07 31
Phone: +33 (0)4 30 30 30 87    Mobile: +33 (0)6 64 18 99 59
investors@innate-pharma.com    caroline@alizerp.com

110107 Half-year report on liquidity agreement

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Half-year report on INNATE PHARMA's liquidity contract with NATIXIS SECURITIES

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories